HER2 peptide vaccine + autologous T-cells

This therapy is a combination immunotherapy regimen involving vaccination with a multiple-peptide-based HER2 (human epidermal growth factor receptor 2) intracellular domain (ICD) peptide vaccine followed by adoptive transfer of ex vivo-expanded, autologous (patient-derived) T cells that have been primed in vivo by the vaccine. The approach aims to generate and expand tumor antigen-specific CD4+ Th1 and CD8+ cytotoxic T-cell responses against tumors overexpressing the HER2 protein, most commonly in advanced or metastatic breast cancer. After vaccination to prime the immune system, leukapheresis is performed to collect peripheral blood mononuclear cells; these are then expanded ex vivo for infusion back into the patient. Booster vaccines may be administered after cell infusions. The mechanism leverages both active immunization and cell therapy to enhance anti-tumor immunity targeting the HER2 antigen[1][2]. Clinical trials have demonstrated feasibility, minimal toxicity, increased survival in responders, and evidence of epitope spreading.

Other names

HER2 vaccine-primed autologous T cellsHER-2 vaccine-primed autologous T cellsHER 2 vaccine-primed autologous T cellsHER2/neu vaccine primed autologous T cellsadoptive transfer of HER2-specific T cells